Praxis Precision Medicines (PRAX) Share-based Compensation (2019 - 2026)

Praxis Precision Medicines' Share-based Compensation history runs 8 years deep, the most recent figure standing at $17.1 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 94.76% year-over-year to $17.1 million; the TTM figure through Mar 2026 stood at $42.3 million (up 18.49% YoY), while the FY2025 annual figure was $33.9 million, down 17.94% from the prior year.
• Share-based Compensation was $17.1 million for Q1 2026 at Praxis Precision Medicines, up from $9.9 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $17.1 million in Q1 2026 to a low of $5.7 million in Q4 2023.
• Historically, Share-based Compensation has averaged $8.6 million across 5 years, with a median of $7.6 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation surged 115.72% in 2024, then tumbled 40.1% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $6.4 million in 2022, then decreased by 10.05% to $5.7 million in 2023, then jumped by 49.76% to $8.6 million in 2024, then climbed by 15.9% to $9.9 million in 2025, then surged by 72.19% to $17.1 million in 2026.
• The last three Share-based Compensation figures came in at $17.1 million (Q1 2026), $9.9 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.